The Senate Judiciary Committee today held a hearing on “a whole-of-government approach” to tackling the opioid crisis. Witnesses included officials from the White House Office of National Drug Control Policy; Department of Justice; Drug Enforcement Administration; Substance Abuse and Mental Health Services Administration; Rand Corporation; Healthcare Distribution Alliance; National Community Pharmacists Association; and Community Anti-Drug Coalitions of America. Among specific recommendations, Committee Ranking Member Dianne Feinstein, D-Calif., and DOJ and DEA officials called for permanently scheduling fentanyl-like substances as Schedule I substances while maintaining access to research on these compounds, noting that DEA’s emergency temporary scheduling action controlling fentanyl-related substances is set to expire Feb. 6. Sen. Patrick Leahy, D-Vt., praised the hub-and-spoke treatment model, of which Vermont was an early adopter, and called for an expansion of rural treatment centers. Other witnesses recommended expanding access to effective treatment for opioid use disorders, stable housing for those recovering from OUD, and a systems approach to data; using pharmacists to expand access to medication-assisted treatment; and additional funding for community coalitions to prevent opioid misuse. 

Related News Articles

Perspective
The federal government has a history of reimbursing hospitals below of the cost of providing care to patients.For Medicare, which covers more than 60 million…
Headline
Hospitals and health systems are prioritizing preserving access to care for patients in rural America, including via access points like hospital outpatient…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Blog
September is National Suicide Prevention Month, with several days that emphasize the opportunity to elevate awareness about the important role everyone can…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Opinion / Editorial
This Op-Ed originally appeared in The Hill. Will the care be there? A confluence of unprecedented challenges over the last three years, including workforce…